Targeting MCL-1/BCL-X(L) Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia

ABT-199, a potent and selective small-molecule antagonist of BCL-2, is being clinically vetted as pharmacotherapy for the treatment of acute myeloid leukemia (AML). However, given that prolonged monotherapy tends to beget resistance, we sought to investigate the means by which resistance to ABT-199...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: Lin, Kevin H., Winter, Peter S., Xie, Abigail, Roth, Cullen, Martz, Colin A., Stein, Elizabeth M., Anderson, Gray R., Tingley, Jennifer P., Wood, Kris C.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4901329/
https://ncbi.nlm.nih.gov/pubmed/27283158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep27696
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados